Tilray Brands, Inc. (TLRY)
USD 0.49
(-0.12%)
USD 0.49
(-0.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 287.93 Million USD | -19.56% |
| 2023 | 365.86 Million USD | -31.12% |
| 2022 | 531.15 Million USD | -40.26% |
| 2021 | 889.05 Million USD | 203.55% |
| 2020 | 292.88 Million CAD | -17.83% |
| 2019 | 356.43 Million CAD | 1521.97% |
| 2018 | 21.97 Million CAD | -6.86% |
| 2017 | 23.59 Million CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 362.76 Million USD | 7.15% |
| 2024 FY | 287.93 Million USD | -21.3% |
| 2024 Q4 | 287.93 Million USD | -1.47% |
| 2024 Q1 | 280.71 Million USD | -23.66% |
| 2024 Q3 | 292.23 Million USD | -0.19% |
| 2023 Q3 | 321.1 Million USD | -16.48% |
| 2023 Q1 | 568.14 Million USD | 6.96% |
| 2023 Q2 | 384.44 Million USD | -32.33% |
| 2023 Q4 | 365.86 Million USD | 13.94% |
| 2023 FY | 365.86 Million USD | -31.12% |
| 2022 Q2 | 755.93 Million USD | -8.91% |
| 2022 Q4 | 531.15 Million USD | -16.81% |
| 2022 FY | 531.15 Million USD | -40.26% |
| 2022 Q1 | 829.88 Million USD | -6.66% |
| 2022 Q3 | 638.49 Million USD | -15.54% |
| 2021 Q2 | 404.67 Million CAD | 30.83% |
| 2021 Q1 | 309.32 Million CAD | 5.61% |
| 2021 Q3 | 707.21 Million CAD | 74.76% |
| 2021 FY | 889.05 Million USD | 203.55% |
| 2021 Q4 | 889.05 Million USD | 25.71% |
| 2020 Q2 | 373.33 Million CAD | 6.93% |
| 2020 Q3 | 351.33 Million CAD | -5.89% |
| 2020 Q4 | 292.88 Million CAD | -16.64% |
| 2020 Q1 | 349.15 Million CAD | -2.04% |
| 2020 FY | 292.88 Million CAD | -17.83% |
| 2019 Q4 | 356.43 Million CAD | 652.42% |
| 2019 FY | 356.43 Million CAD | 1521.97% |
| 2019 Q2 | 38.53 Million CAD | -3.78% |
| 2019 Q3 | 47.37 Million CAD | 22.93% |
| 2019 Q1 | 40.05 Million CAD | 82.25% |
| 2018 FY | 21.97 Million CAD | -6.86% |
| 2018 Q3 | 23.55 Million CAD | -2.27% |
| 2018 Q4 | 21.97 Million CAD | -6.72% |
| 2018 Q2 | 24.1 Million CAD | -2.97% |
| 2018 Q1 | 24.84 Million CAD | 5.29% |
| 2017 Q3 | 5.44 Million CAD | 7.5% |
| 2017 Q1 | 5.34 Million CAD | 0.0% |
| 2017 Q2 | 5.06 Million CAD | -5.19% |
| 2017 Q4 | 23.59 Million CAD | 333.25% |
| 2017 FY | 23.59 Million CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 41.233% |
| Embecta Corp. | 1.62 Billion USD | 82.285% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 7.018% |
| Dynavax Technologies Corporation | 252.41 Million USD | -14.071% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 42.591% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 43.959% |
| PainReform Ltd. | 30 Thousand USD | -959683.333% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -216.148% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -53316.754% |
| SCYNEXIS, Inc. | 12.15 Million USD | -2268.081% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -245727.25% |
| Cosmos Health Inc. | 3.03 Million USD | -9386.084% |
| Journey Medical Corporation | 14.62 Million USD | -1869.19% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -53316.754% |
| Safety Shot Inc | 304.9 Thousand USD | -94333.713% |
| Alpha Teknova, Inc. | 13.25 Million USD | -2072.93% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -2060.701% |
| Bright Green Corporation | 201.78 Thousand USD | -142595.371% |
| Procaps Group, S.A. | 28.41 Million USD | -913.499% |
| Theratechnologies Inc. | 51.26 Million USD | -461.704% |
| Harrow Health, Inc. | 183.17 Million USD | -57.194% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -330859.77% |
| Biofrontera Inc. | 804 Thousand USD | -35712.811% |
| DURECT Corporation | 2.7 Million USD | -10556.366% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -767.379% |
| Cronos Group Inc. | 1.55 Million USD | -18369.211% |
| OptiNose, Inc. | 611 Thousand USD | -47025.205% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 42.218% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -742.161% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -63182.418% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -374.006% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -2152.282% |
| Radius Health, Inc. | 339.66 Million USD | 15.23% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -2706.931% |
| Phibro Animal Health Corporation | 458.28 Million USD | 37.172% |
| Procaps Group S.A. | 28.41 Million USD | -913.499% |
| Alvotech | 1.02 Billion USD | 71.984% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -4308.068% |
| Viatris Inc. | 16.18 Billion USD | 98.221% |
| Rockwell Medical, Inc. | 8.29 Million USD | -3372.025% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -2547.191% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -85597.236% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -138.93% |
| Shineco, Inc. | 10.01 Million USD | -2774.368% |
| PetIQ, Inc. | 437.82 Million USD | 34.234% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -137011.905% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -11.473% |
| Alimera Sciences, Inc. | 64.48 Million USD | -346.487% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -647.611% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -213044.668% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -4098.917% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -39890.972% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1280521.775% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -778.922% |
| Hempacco Co., Inc. | 5.93 Million USD | -4754.745% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 71.984% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -412.194% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 53.267% |
| Currenc Group, Inc. | 2.5 Million USD | -11385.36% |
| Kamada Ltd. | 7.43 Million USD | -3771.135% |
| Indivior PLC | 235.66 Million USD | -22.179% |
| Evoke Pharma, Inc. | 5 Million USD | -5658.7% |
| Flora Growth Corp. | 942 Thousand USD | -30466.348% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1280521.775% |
| Evolus, Inc. | 120.35 Million USD | -139.23% |
| HUTCHMED (China) Limited | 48.18 Million USD | -497.512% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 51.131% |
| Akanda Corp. | 2.49 Million USD | -11430.522% |